Compare Abbott Laboratories (ABT) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Tesla, Inc. — how do they compare? Abbott Laboratories trades at $109.35 (market cap $187.95B), while Tesla, Inc. trades at $334.21 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 7× Abbott Laboratories's market cap, and Abbott Laboratories pays a 2.32% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| ABT | TSLA | |
|---|---|---|
Market Cap | $187.95B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $489.88 |
52-Week Low | $82.57 | $298.16 |
Enterprise Value | $214.96B | $1.29T |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Tesla (TSLA) trades at $330.87, up 0.7% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key resistance at $333 and support at $327, while fundamentals reveal high valuation multiples (P/E 306.37) and declining profit margins (net margin 3.67% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing near-term delivery misses with long-term innovation bets.
Tesla's outlook hinges on executing its pivot to AI and autonomy amid slowing auto growth. Investment opportunities lie in market leadership in self-driving technology and energy expansion, but risks include intense EV competition, execution challenges, and rich valuations that demand flawless growth. Wall Street remains divided, with a $393.87 consensus target suggesting upside if catalysts materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
